Mesoblast hit with shareholder class action over stem cell treatment

Class Actions 2022-05-19 4:16 pmBy Sam Matthews | Melbourne

Please login to bookmark

Regenerative medicine company Mesoblast is facing another class action over claims it misled shareholders about the potential application of a developmental stem cell product to treat terminally ill children.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au